Nature Medicine, Published online: 31 March 2026; doi:10.1038/d41591-026-00018-2 In the phase 3 EVOKE(+) trials, semaglutide did not slow clinical progression of Alzheimer’s disease, but the findings provide new insights in the ongoing quest for treatments.
Nature Medicine published a clinical update in Research Highlights on 31 Mar 2026.
The item focuses on GLP-1 receptor agonist fails to halt Alzheimer’s disease.
Review the original article for the full source wording and details.